Nama's AI scorecard currently rates Hinge Health Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is HNGE's P/E ratio?

Hinge Health trades at a trailing price-to-earnings ratio of 51.7.

When does HNGE report earnings?

Hinge Health's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $0.60.

What is the HNGE price target?

The median analyst price target from 16 analysts is $135.00, with a range of $90.00 – $151.00.

Is HNGE Shariah compliant?

Nama's AAOIFI-style screen reads Hinge Health as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Hinge Health (HNGE)

Healthcare · Health Information Services · NYSE

Hinge Health (HNGE) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $9.34B, a trailing price-to-earnings ratio of 51.7 and a free-cash-flow yield of 2.6%. Over the most recent reported fiscal year, revenue grew 50.6% and free cash flow per share grew 422.7%. Nama's AI scorecard rates it Buy, 6.9 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 6.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +122.2% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-7.3%

How far the last close sits under the highest price of the past five years.

Market cap	$9.34B
Trailing P/E	51.7
Price / book	27.0
Price / sales	13.0
FCF yield	2.6%
Dividend yield	—
Gross margin	84.5%
Operating margin	13.0%
Net margin	15.2%
Revenue growth (YoY)	+50.6%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	+422.7%
Beta	—
Exchange	NYSE
Sector	Healthcare
Industry	Health Information Services

HNGE earnings

Next report: Feb 9, 2027 (Q4 2026, EPS estimate $0.60). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$0.71	$0.60	+18.3%	—
Q2 2026	Aug 4, 2026	$0.59	$0.62	-4.8%	$212.82M
Q1 2026	May 5, 2026	$0.45	$0.40	+12.5%	$182.31M
Q4 2025	Feb 10, 2026	$0.49	$0.43	+13.9%	$170.73M

HNGE analyst price target

Median target $135.00 from 16 analysts, ranging $90.00 – $151.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
VEEV	Veeva Systems	$49.18B	35.0
TEM	Tempus AI	$13.87B	—
BTSG	BrightSpring Health Services	$13.36B	39.3
HQY	HealthEquity	$8.57B	23.3
TXG	10x Genomics	$7.72B	296.4
DOCS	Doximity	$5.79B	23.7
WAY	Waystar	$5.45B	17.2
HTFL	Heartflow	$4.56B	—

Explore live HNGE data on Nama Insights →

HNGE FAQ

Is HNGE a buy?: Nama's AI scorecard currently rates Hinge Health Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is HNGE's P/E ratio?: Hinge Health trades at a trailing price-to-earnings ratio of 51.7.
When does HNGE report earnings?: Hinge Health's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $0.60.
What is the HNGE price target?: The median analyst price target from 16 analysts is $135.00, with a range of $90.00 – $151.00.
Is HNGE Shariah compliant?: Nama's AAOIFI-style screen reads Hinge Health as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.